Monitor for upcoming updates on GMP manufacturing progress and clinical trial application filings, which are critical path items for the Q4 2026 study launch. Absence of such updates may signal delays.
Price Chart
Executive Summary
Propanc Biopharma announced a service agreement with FyoniBio GmbH to develop and validate a pharmacokinetics (PK) assay for its lead asset PRP ahead of a Phase 1b First-In-Human study in advanced cancer patients. The assay will enable quantification of PRP and its components in human serum, supporting clinical decision-making for the planned Q4 2026 trial initiation.
Key Facts
- Propanc executed a service agreement with FyoniBio GmbH to establish and validate an LC-MS-based PK assay for its lead candidate PRP.
- The PK assay will quantify trypsinogen, chymotrypsinogen, trypsin, and chymotrypsin in human serum during a Phase 1b First-In-Human study.
- Assay sensitivity target is at least 0.1 µg/mL, sufficient for monitoring PRP levels in clinical trials.
- The Phase 1b study is planned to commence in Q4 2026.
- This is one of three key preparatory activities, alongside GMP manufacturing and clinical trial application.
Financial Impact
No financial terms disclosed; likely a routine R&D expense with minimal near-term financial impact.
Risk Factors
- Risk of delay or failure in assay validation, which could push back clinical trial initiation.
- No funding or cost details disclosed — potential cash flow pressure on a $3M market cap company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252839 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | — |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | — |
Sep 29, 2026 27d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | — |
Aug 18, 2026 9w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | — |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | — |
May 19, 2026 22w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | — |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | — |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | — |
Apr 21, 2026 26w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | — |
Mar 24, 2026 30w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers